The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Top Cited Papers
Open Access
- 1 July 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 377 (9784), 2181-2192
- https://doi.org/10.1016/s0140-6736(11)60739-3
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialThe Lancet, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyThe New England Journal of Medicine, 2008
- The Second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: A Randomized Controlled Study of the Biochemical Safety and Efficacy of Adding Ezetimibe to Simvastatin as Initial Therapy Among Patients With CKDAmerican Journal of Kidney Diseases, 2006
- First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2005
- EzetimibeClinical Pharmacokinetics, 2005
- Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney DiseaseCirculation, 2004
- Estimating the effect of the run‐in on the power of the physicians' health studyStatistics in Medicine, 1991